Characteristics of acute myeloid leukemia with myelodysplasia-related changes: A retrospective analysis in a cohort of Chinese patients

American Journal of Hematology

Volumn 89, Issue 9, 2014, Pages 874-881

  Xu, Xiao Qian ^a   Wang, Jian Min ^a   Gao, Lei ^a   Qiu, Hui Ying ^a   Chen, Li ^a   Jia, Lin ^a   Hu, Xiao Xia ^a   Yang, Jian Min ^a   Ni, Xiong ^a   Chen, Jie ^a   Lü, Shu Qing ^a   Zhang, Wei Ping ^a   Song, Xian Min ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ACLARUBICIN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HOMOHARRINGTONINE; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGRESSION; CHINESE; CHROMOSOME ABERRATION; CYTOGENETICS; DISEASE FREE SURVIVAL; DISEASE PREDISPOSITION; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; HUMAN CELL; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CCAAT-ENHANCER-BINDING PROTEINS; CHINA; COHORT STUDIES; CYTOGENETIC ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; KARYOTYPE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; MYELODYSPLASTIC SYNDROMES; NUCLEAR PROTEINS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84906076578     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23772     Document Type: Article

References (21)

1. Brito-Babapulle F, Catovsky D, Galton DA. Clinical and laboratory features of de novo acute myeloid leukaemia with trilineage myelodysplasia. Br J Haematol 1987;66:445-450.
2. Jaffe ES, Harris NL, Stein H, et al. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours, 3rd ed. Lyon, France: IARC Press; 2001.
3. Swerdlow S, Campo E, Lee Harris N, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon, France: IARC Press; 2008.
4. Wandt H, Haferlach T, Thiede C, et al. WHO classification of myeloid neoplasms and leukemia. Blood 2010;115:748-749.
5. Adachi S, Manabe A, Imaizumi M, et al. Acute myeloid leukemia with multilineage dysplasia in children. Int J Hematol 2007;86:358-363.
6. Kuriyama K, Tomonaga M, Matsuo T, et al. Poor response to intensive chemotherapy in de novo acute myeloid leukaemia with trilineage myelodysplasia. Japan Adult Leukaemia Study Group (JALSG). Br J Haematol 1994;86:767-773.
7. Meckenstock G, Aul C, Hildebrandt B, et al. Dyshematopoiesis in de novo acute myeloid leukemia: Cell biological features and prognostic significance. Leuk Lymphoma 1998;29:523-531.
8. Zhu XH, Xia XM, Li JY. Clinical observation on the biological characteristic and the therapeutic effect in de novo acute myeloid leukemia with multilineage dysplasia. Suzhou Univ J Med Sci 2002;22:282-283.
9. Estienne MH, Fenaux P, Preudhomme C, et al. Prognostic value of dysmyelopoietic features in de novo acute myeloid leukemia: a report on 132 patients. Clin Lab Haematol 1990;12:57-65.
10. Miyazaki Y, Kuriyama K, Miyawaki S, et al. Cytogenetic heterogeneity of acute myeloid leukaemia (AML) with trilineage dysplasia. Br J Haematol 2003;120:56-62.
11. Gahn B, Haase D, Unterhalt M, et al. De novo AML with dysplastic hematopoiesis: Cytogenetic and prognostic significance. Leukemia 1996;10:946-951.
12. Weinberg OK, Seetharam M, Ren L, et al. Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. Blood 2009;113:1906-1908.
13. Arber DA, Stein AS, Carter NH, et al. Importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival. Am J Clin Pathol 2003;119:672-680.
14. Goasguen JE, Matsuo T, Cox C, et al. Evaluation of the dysmyelopoiesis in 336 patients with de novo acute myeloid leukemia: major importance of dysgranulopoiesis for remission and survival. Leukemia 1992;6:520-525.
15. Kahl C, Florschütz A, Müller G, et al. Prognostic significance of dysplastic features of hematopoiesis in patients with de novo acute myelogenous leukemia. Ann Hematol 1997;75:91-94.
16. Wandt H, Schäkel U, Kroschinsky F, et al. MLD according to the WHO classification in AML has no correlation with age and no independent prognostic relevance as analyzed in 1766 patients. Blood 2008;111:1855-1861.
17. Haferlach T, Schoch C, Löffler H, et al. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: Results of a multiparameter analysis from the German AML Cooperative Group studies. J Clin Oncol 2003;21:256-265.
18. Falini B, Macijewski K, Weiss T, et al. Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). Blood 2010;115:3776-3786.
19. Miesner M, Haferlach C, Bacher U, et al., Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: A comparison of 408 cases classified as "AML not otherwise specified" (AML-NOS) or "AML with myelodysplasia-related changes" (AML-MRC). Blood 2010;116:2742-2751.
20. Yanada M, Suzuki M, Kawashima K, et al. Long-term outcomes for unselected patients with acute myeloid leukemia categorized according to the World Health Organization classification: A single center experience. Eur J Haematol 2005;74:418-423.
21. Bacher U, Schnittger S, Macijewski K, et al. Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity. Blood 2012;119:4719-4722.